Proficio Capital Partners LLC bought a new stake in Envista Holdings Co. (NYSE:NVST - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 18,576 shares of the company's stock, valued at approximately $358,000.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Venturi Wealth Management LLC lifted its holdings in Envista by 528.4% in the fourth quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company's stock valued at $38,000 after acquiring an additional 1,638 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Envista by 30.5% in the 4th quarter. GAMMA Investing LLC now owns 2,304 shares of the company's stock valued at $44,000 after purchasing an additional 538 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Envista in the 4th quarter valued at $53,000. KBC Group NV grew its holdings in shares of Envista by 63.9% during the 4th quarter. KBC Group NV now owns 7,903 shares of the company's stock worth $152,000 after purchasing an additional 3,082 shares during the period. Finally, Sanctuary Advisors LLC acquired a new stake in shares of Envista during the 3rd quarter worth about $228,000.
Wall Street Analyst Weigh In
A number of research analysts have commented on the stock. Wells Fargo & Company set a $19.00 target price on shares of Envista in a research note on Saturday, March 8th. Morgan Stanley decreased their price objective on shares of Envista from $20.00 to $19.00 and set an "equal weight" rating on the stock in a report on Thursday, March 6th. Mizuho started coverage on shares of Envista in a report on Wednesday, December 4th. They issued an "underperform" rating and a $20.00 target price for the company. Piper Sandler upped their price target on Envista from $17.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, February 3rd. Finally, UBS Group dropped their price objective on Envista from $23.00 to $21.00 and set a "neutral" rating for the company in a research note on Monday, March 10th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $20.18.
Read Our Latest Stock Analysis on Envista
Envista Stock Down 5.9 %
NYSE:NVST traded down $1.07 during mid-day trading on Friday, hitting $16.96. The stock had a trading volume of 6,605,419 shares, compared to its average volume of 2,421,373. The company has a current ratio of 2.04, a quick ratio of 1.76 and a debt-to-equity ratio of 0.44. Envista Holdings Co. has a twelve month low of $15.15 and a twelve month high of $23.00. The company has a market capitalization of $2.92 billion, a PE ratio of -2.61, a PEG ratio of 1.27 and a beta of 1.33. The stock has a 50-day simple moving average of $19.59 and a two-hundred day simple moving average of $19.60.
Envista (NYSE:NVST - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. On average, equities research analysts anticipate that Envista Holdings Co. will post 1 EPS for the current year.
About Envista
(
Free Report)
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Featured Articles
Before you consider Envista, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Envista wasn't on the list.
While Envista currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
